@article{ref1,
title="Reduction in self-harming behaviour after zuclopenthixol decanoate",
journal="Progress in Neurology and Psychiatry",
year="2014",
author="Javed, Q. and Chorghade, A. and Javed, S. and Pervez, Y.",
volume="18",
number="4",
pages="23-27",
abstract="No psychotropic drug is specifically licensed for the management of emotionally unstable borderline personality disorder. Prescribing 'off-label' places additional responsibilities on the prescriber and may increase liability if there are adverse effects. This case report describes a patient with borderline personality disorder who was started on zuclopenthixol decanoate with successful outcome in terms of reducing self-harming behaviour and impulsivity. © 2014 John Wiley and Sons, Ltd.<p /><p>Language: en</p>",
language="en",
issn="1367-7543",
doi="10.1002/pnp.340",
url="http://dx.doi.org/10.1002/pnp.340"
}